Comparison · NCT01064401-sae
IFN Beta-1a 30 mcg vs DAC HYP 150 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IFN Beta-1a 30 mcg vs DAC HYP 150 mg: serious adverse events. Trial comparisons, record NCT01064401-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01064401-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.21 | 0.185 | 0.238 | wilson | |
| Risk in group 2 | 0.24 | 0.214 | 0.269 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0301 | -0.0682 | 0.00812 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.875 | 0.738 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.842 | 0.676 | 1.05 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on IFN Beta-1a 30 mcg than on DAC HYP 150 mg | 33.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IFN Beta-1a 30 mcg | IFN β-1a 30 µg IM injection once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks | 194 | 922 | EG000 |
| Group 2 | DAC HYP 150 mg | DAC HYP 150 mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks | 221 | 919 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All events were collected from Baseline through Week 164 (end of Post-dosing period).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
- NCT number
- NCT01064401
- Phases
- PHASE3
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
- Lead sponsor
- Biogen
- Results first posted
- 2016-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01064401?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01064401-sae